BHCCF:OTC-Benchmark Holdings plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | OTC

Last Closing Price

USD 0.79

Change

0.00 (0.00)%

Market Cap

USD 0.33B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge for the development of food and farming industries worldwide. The company operates through Animal Health, Benchmark Genetics, Advanced Animal Nutrition, and All Other segments. The Animal Health segment provides veterinary and environmental diagnostics services, and animal health products to aquaculture, as well as manufactures licensed veterinary vaccines and components. The Benchmark Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide a range of genetic merit ova. The Advanced Animal Nutrition segment manufactures and offers nutrition and health products to the aquaculture industry. The All Other segment provides sustainable food production and technical consultancy, and assurance services; and promotes sustainable food production and ethics through online news and technical publications for the international agriculture and food processing sectors, as well as through delivery of training courses to industries. Benchmark Holdings plc was founded in 2000 and is headquartered in Sheffield, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-13 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BIOGY BioGaia AB (publ)

N/A

USD0.80B 36.20 -264.23
LJUIF SSY Group Limited

N/A

USD-1,669,326,336.00 26.57 12.23

ETFs Containing BHCCF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers - Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.28% 100% A+ 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.28% 100% A+ 28% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.29% 33% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.29% 33% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 5.73% 100% A+ 97% A+
Risk Adjusted Return -22.52% 33% F 17% F
Market Capitalization 0.33B 50% F 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers - Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 75.60 50% F 10% F
Price/Book Ratio 0.65 100% A+ 79% C+
Price / Cash Flow Ratio -88.53 100% A+ 94% A
EV/EBITDA -12.10 50% F 95% A
Management Effectiveness  
Return on Equity -1.18% 50% F 44% F
Return on Invested Capital 0.53% 50% F 50% F
Return on Assets -0.83% 50% F 48% F
Debt to Equity Ratio 20.97% 100% A+ 55% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.09 50% F 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.